A Heterogeneous Tumor Immune Microenvironment of Uncommon Epidermal Growth Factor Receptor Mutant Non-small Cell Lung Cancer

Overview

Journal Cancer Sci

Specialty Oncology

Date 2024 Jun 19

PMID 38890815

Authors

Chong Zhang

Liangwei Yang

Weidi Zhao

Huangkai Zhu

Shuo Shi

Songan Chen

Guoqiang Wang

Bing Li

Guofang Zhao

Affiliations

Soon will be listed here.

Abstract

Common epidermal growth factor receptor (EGFR) mutations are usually not considered for immunotherapy in non-small cell lung cancer (NSCLC) due to poor efficacy. However, whether uncommon EGFR mutations are suitable for immunotherapy has not been thoroughly studied. Thus, we explored the tumor immune microenvironment (TME) features in uncommon EGFR mutant NSCLC. In this study, a total of 41 patients with EGFR mutations were included, the majority (85.4%) of whom were stage I. Among them, 22 patients harbored common mutations, while 19 patients presented with uncommon mutations. Compared with common mutations, uncommon mutations exhibited more infiltrating T cells and fewer M2 macrophages, upregulated expression of antigen processing and a presentation pathway. Unsupervised clustering based on the mIF profile identified two classes with heterogeneous TME in uncommon mutations. Class 1 featured the absence of PD-1 cytotoxic T cell infiltration, and class 2 displayed a hotter TME because of the downregulated expression of hypoxia (p < 0.001), oxidative phosphorylation (p = 0.009), and transforming growth factor beta signaling (p = 0.01) pathways as well as increased expression of CTLA4 (p = 0.001) and PDCD1 (p = 0.004). The association of CTLA4 and PDCD1 with TME profiles was validated in a TCGA lung adenocarcinoma cohort with uncommon EGFR mutations. Our study reveals the distinct and heterogeneous TME features in uncommon EGFR mutant NSCLC.

Citing Articles

A heterogeneous tumor immune microenvironment of uncommon epidermal growth factor receptor mutant non-small cell lung cancer.

Zhang C, Yang L, Zhao W, Zhu H, Shi S, Chen S Cancer Sci. 2024; 115(9):3143-3152.

PMID: 38890815 PMC: 11462928. DOI: 10.1111/cas.16253.

References

Anders S, Pyl P, Huber W . HTSeq--a Python framework to work with high-throughput sequencing data. Bioinformatics. 2014; 31(2):166-9. PMC: 4287950. DOI: 10.1093/bioinformatics/btu638. View

Mazieres J, Drilon A, Lusque A, Mhanna L, Cortot A, Mezquita L . Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann Oncol. 2019; 30(8):1321-1328. PMC: 7389252. DOI: 10.1093/annonc/mdz167. View

Herbst R, Baas P, Kim D, Felip E, Perez-Gracia J, Han J . Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2015; 387(10027):1540-1550. DOI: 10.1016/S0140-6736(15)01281-7. View

Yoshida H, Kim Y, Ozasa H, Nagai H, Sakamori Y, Tsuji T . Nivolumab in non-small-cell lung cancer with EGFR mutation. Ann Oncol. 2017; 29(3):777-778. DOI: 10.1093/annonc/mdx745. View

Jin R, Liu C, Zheng S, Wang X, Feng X, Li H . Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer. Cancer Biol Med. 2020; 17(3):768-781. PMC: 7476088. DOI: 10.20892/j.issn.2095-3941.2020.0121. View

To K, Fong W, Cho W . Immunotherapy in Treating EGFR-Mutant Lung Cancer: Current Challenges and New Strategies. Front Oncol. 2021; 11:635007. PMC: 8185359. DOI: 10.3389/fonc.2021.635007. View

Wu Y, Zhou C, Hu C, Feng J, Lu S, Huang Y . Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol. 2014; 15(2):213-22. DOI: 10.1016/S1470-2045(13)70604-1. View

Batlle E, Massague J . Transforming Growth Factor-β Signaling in Immunity and Cancer. Immunity. 2019; 50(4):924-940. PMC: 7507121. DOI: 10.1016/j.immuni.2019.03.024. View

Yamada T, Hirai S, Katayama Y, Yoshimura A, Shiotsu S, Watanabe S . Retrospective efficacy analysis of immune checkpoint inhibitors in patients with EGFR-mutated non-small cell lung cancer. Cancer Med. 2019; 8(4):1521-1529. PMC: 6488155. DOI: 10.1002/cam4.2037. View

10.

Patro R, Duggal G, Love M, Irizarry R, Kingsford C . Salmon provides fast and bias-aware quantification of transcript expression. Nat Methods. 2017; 14(4):417-419. PMC: 5600148. DOI: 10.1038/nmeth.4197. View

11.

Toki M, Mani N, Smithy J, Liu Y, Altan M, Wasserman B . Immune Marker Profiling and Programmed Death Ligand 1 Expression Across NSCLC Mutations. J Thorac Oncol. 2018; 13(12):1884-1896. PMC: 6251746. DOI: 10.1016/j.jtho.2018.09.012. View

12.

Miao D, Margolis C, Vokes N, Liu D, Taylor-Weiner A, Wankowicz S . Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors. Nat Genet. 2018; 50(9):1271-1281. PMC: 6119118. DOI: 10.1038/s41588-018-0200-2. View

13.

Kitadai R, Okuma Y . Treatment Strategies for Non-Small Cell Lung Cancer Harboring Common and Uncommon EGFR Mutations: Drug Sensitivity Based on Exon Classification, and Structure-Function Analysis. Cancers (Basel). 2022; 14(10). PMC: 9139782. DOI: 10.3390/cancers14102519. View

14.

Bolger A, Lohse M, Usadel B . Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics. 2014; 30(15):2114-20. PMC: 4103590. DOI: 10.1093/bioinformatics/btu170. View

15.

Love M, Huber W, Anders S . Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014; 15(12):550. PMC: 4302049. DOI: 10.1186/s13059-014-0550-8. View

16.

Chen K, Cheng G, Zhang F, Zhu G, Xu Y, Yu X . PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy. Lung Cancer. 2020; 142:98-105. DOI: 10.1016/j.lungcan.2020.02.010. View

17.

Li T, Pang X, Wang J, Wang S, Guo Y, He N . Exploration of the Tumor-Suppressive Immune Microenvironment by Integrated Analysis in -Mutant Lung Adenocarcinoma. Front Oncol. 2021; 11:591922. PMC: 8200668. DOI: 10.3389/fonc.2021.591922. View

18.

Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H . Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010; 362(25):2380-8. DOI: 10.1056/NEJMoa0909530. View

19.

Zhang T, Wan B, Zhao Y, Li C, Liu H, Lv T . Treatment of uncommon mutations in non-small cell lung cancer: new evidence and treatment. Transl Lung Cancer Res. 2019; 8(3):302-316. PMC: 6626855. DOI: 10.21037/tlcr.2019.04.12. View

20.

Zhang C, Yang L, Zhao W, Zhu H, Shi S, Chen S . A heterogeneous tumor immune microenvironment of uncommon epidermal growth factor receptor mutant non-small cell lung cancer. Cancer Sci. 2024; 115(9):3143-3152. PMC: 11462928. DOI: 10.1111/cas.16253. View